London Health Sciences Centre Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2016
NCT02676739
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

adderall (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 3)

Multiple Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1